New CRISPR-based research tool delivers results in an hour in a one-step reaction; Researchers share protocol and kits to advance research and move toward clinical validation.
The diagnostic platform CARMEN combines microfluidics with the CRISPR-based detection technology SHERLOCK, and could one day be used for public health efforts.
Broad Institute, MIT, Harvard, Massachusetts General Hospital, Rutgers, Skoltech, Wageningen, UTokyo collaborate to advance use of groundbreaking diagnostic
New technique enables SHERLOCK to detect a virus directly in bodily fluids, eliminating a step that required lab equipment and expanding the platform’s potential to quickly and cheaply track pathogens such as Ebola, Zika, and Lassa fever anywhere in the world
A strip of paper can now indicate presence of pathogens, tumor DNA, or any genetic signature of interest. 100-fold greater sensitivity, the ability to detect multiple targets at once, and other new features further enhance SHERLOCK's power for detecting genetic signatures.